Welcome to our dedicated page for Verastem news (Ticker: VSTM), a resource for investors and traders seeking the latest updates and insights on Verastem stock.
Verastem Oncology develops and commercializes oncology medicines for RAS/MAPK pathway-driven cancers. The company markets AVMAPKI FAKZYNJA CO-PACK in the U.S. for KRAS-mutated recurrent low-grade serous ovarian cancer and reports commercial updates, product revenue, and medical-conference data for the avutometinib and defactinib combination.
Recurring VSTM news also covers the company’s small-molecule pipeline, including RAF/MEK inhibition, FAK inhibition, and VS-7375, an oral KRAS G12D inhibitor studied in KRAS G12D-mutant solid tumors. Company updates commonly include clinical-trial analyses from RAMP studies, preclinical research presentations, FDA-related treatment context, patient advocacy resources for LGSOC, executive and employee equity grants, and quarterly financial results.
Verastem Oncology (Nasdaq: VSTM) granted equity awards under Nasdaq Listing Rule 5635(c)(4) to new employees. The company issued 399,750 restricted stock units (RSUs) to 30 hires and stock options for 91,000 shares to one hire at a $4.10 exercise price.
Most RSUs and all options vest 25% after one year, then quarterly over three years, subject to continued service. An additional 6,000 RSUs for one employee vest in full after one year of service.
Verastem Oncology (Nasdaq: VSTM) reported preliminary Phase 1/2 TARGET-D 101 data for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, in advanced KRAS G12D-mutated solid tumors.
According to Verastem, VS-7375 showed anti-tumor activity across pancreatic, colorectal and lung cancers with a favorable, mainly low-grade gastrointestinal safety profile, both as monotherapy and in combinations with cetuximab or gemcitabine/nab-paclitaxel.
Verastem Oncology (Nasdaq: VSTM) reported updated Phase 1b/2a RAMP 205 results for avutometinib plus defactinib with gemcitabine and nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma.
Among 29 patients (90% metastatic at diagnosis), 6‑month overall survival was 86%, 6‑month PFS 68%, confirmed ORR 52%, and 83% had tumor shrinkage, with no new safety signals observed.
Verastem Oncology (Nasdaq: VSTM) dosed the first patient in TARGET-D 201, a Phase 2 registration-directed trial of VS-7375, an investigational oral KRAS G12D (ON/OFF) inhibitor, for KRAS G12D-mutated metastatic pancreatic ductal carcinoma.
The study evaluates 900 mg once-daily VS-7375 as monotherapy and with full-dose cetuximab in second-line mPDAC, and the VS-7375/cetuximab combination in first-line mPDAC. VS-7375 previously received FDA Fast Track designation for KRAS G12D-mutated advanced or metastatic pancreatic cancer.
Verastem Oncology (Nasdaq: VSTM) will host an investor conference call and webcast on June 23, 2026, at 4:30 p.m. ET. Management plans to review progress in the VS-7375 oral KRAS G12D (ON/OFF) TARGET-D program and updated preliminary Phase 1/2 TARGET-D 101 data.
The trial evaluates VS-7375 alone and in combination in KRAS G12D-mutated advanced solid tumors, including pancreatic, colorectal, and non-small lung cancers. The call will cover safety, tolerability, pharmacokinetics, and patient case studies. A live and archived webcast will be accessible via the company’s investor website.
Verastem Oncology (Nasdaq: VSTM) received U.S. FDA Fast Track Designation for VS-7375, an oral investigational selective KRAS G12D (ON/OFF) inhibitor, in adults with KRAS G12D-mutated unresectable locally advanced or metastatic NSCLC after platinum chemotherapy and anti‑PD-(L)1 therapy.
According to Verastem, VS-7375 already has Fast Track for KRAS G12D-mutated pancreatic cancer. The company is running Phase 1/2 TARGET-D 101 and three registration-directed Phase 2 trials (TARGET-D 201, 202, 203), with early data expected in 1H 2026 and more mature readouts in 2H 2026.
Verastem Oncology (Nasdaq: VSTM) will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026, at 8:10 a.m. ET in New York.
A live webcast and a replay (available for about 90 days) will be hosted on Verastem’s website under “Events & Presentations.”
Verastem Oncology (Nasdaq: VSTM) appointed Michael P. Bailey to its Board of Directors, effective after Robert Gagnon’s term ended on May 21, 2026. Bailey brings over 30 years of global pharma and biotech leadership, including leading AVEO’s sale to LG Chem and commercializing oncology drugs such as ERBITUX.
According to Verastem, his expertise is expected to support growth of AVMAPKI FAKZYNJA CO-PACK and advance VS-7375, an oral KRAS G12D (ON/OFF) inhibitor targeting cancers with no approved therapies.
Verastem Oncology (Nasdaq: VSTM) will present at two investor conferences in New York City in May 2026. Management participates in the HCW 4th Annual BioConnect Investor Conference on May 19 and the RBC Global Healthcare Conference on May 20, with live and archived webcasts available.
Verastem Oncology (NASDAQ: VSTM), STAAR Low-Grade Serous Ovarian Cancer Foundation, and Not These Ovaries launched the LGSOC Resource Guide on May 8, 2026 for World Ovarian Cancer Day. Available at www.LGSOCAwarenessDay.org, the guide aggregates educational materials, community resources, and advocacy content for patients, caregivers, and clinicians focused on low-grade serous ovarian cancer.
The guide compiles resources from dozens of organizations, covers diagnosis, treatment, fertility, survivorship, and caregiver support, and notes that content may become outdated as research evolves.